Abstract
Allogeneic hematopoietic cell transplantation has developed into a most successful form of immunotherapy for hematologic malignancies in the past 50 years. However, its effectiveness and wider applications have been greatly limited by the development of graft-versus-host disease (GVHD), a potentially lethal side effect associated with this procedure. Since the main effectors for both graft-versus-leukemia (GVL) effect and GVHD are T lymphocytes and these two processes share many similar pathways, it has not been easy to separate GVL from GVHD. Because the clinically used pan immunosuppressive therapy for GVHD prevention also results in decreased GVL effect, the success of allogeneic hematopoietic cell transplantation relies on a small and unpredictable therapeutic window at the present time. This review discusses how we may widen this therapeutic window so that we can reliably prevent GVHD without losing GVL effect.
Similar content being viewed by others
References
De Vries MJ, Vos O. Treatment of mouse lymphosarcoma by total-body x-irradiation and by injection of bone marrow and lymph-node cells. J Natl Cancer Inst. 1958;21(6):1117–29.
Mathe G, Bernard J. Trial therapy, by x-irradiation followed by the administration of homologous bone marrow cells, of highly-advanced spontaneous leukemia in AK mice. Bull Assoc Fr Etud Cancer. 1958;45(3):289–300.
van Bekkum DW, de Vries VB. Radiation Cbimeras. London: Logos Ltd; 1967. p. 1–277.
Weiden PL, et al. Antileukemic effect of chronic graft-versus-host disease: contribution to improved survival after allogeneic marrow transplantation. N Engl J Med. 1981;304(25):1529–33.
Urbano-Ispizua A, et al. The number of donor CD3(+) cells is the most important factor for graft failure after allogeneic transplantation of CD34(+) selected cells from peripheral blood from HLA-identical siblings. Blood. 2001;97(2):383–7.
Urbano-Ispizua A, et al. Risk factors for acute graft-versus-host disease in patients undergoing transplantation with CD34 + selected blood cells from HLA-identical siblings. Blood. 2002;100(2):724–7.
Aversa F, et al. Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype. N Engl J Med. 1998;339(17):1186–93.
Fowler DH, et al. Allospecific CD8 + Tc1 and Tc2 populations in graft-versus-leukemia effect and graft-versus-host disease. J Immunol. 1996;157(11):4811–21.
Korngold R, Sprent J. T cell subsets and graft-versus-host disease. Transplantation. 1987;44(3):335–9.
Satake A, et al. Separation of antileukemic effects from graft-versus-host disease in MHC-haploidentical murine bone marrow transplantation: participation of host immune cells. Int J Hematol. 2010;91(3):485–97.
Martin PJ, et al. A phase I–II clinical trial to evaluate removal of CD4 cells and partial depletion of CD8 cells from donor marrow for HLA-mismatched unrelated recipients. Blood. 1999;94(7):2192–9.
Nimer SD, et al. Selective depletion of CD8 + cells for prevention of graft-versus-host disease after bone marrow transplantation. A randomized controlled trial. Transplantation. 1994;57(1):82–7.
Champlin R, et al. Selective depletion of CD8-positive T-lymphocytes for allogeneic bone marrow transplantation: engraftment, graft-versus-host disease and graft-versus leukemia. Prog Clin Biol Res. 1992. 377:385–94; discussion 395–8.
Champlin R, et al. Selective depletion of CD8 + T lymphocytes for prevention of graft-versus-host disease after allogeneic bone marrow transplantation. Blood. 1990;76(2):418–23.
Alyea EP, et al. Toxicity and efficacy of defined doses of CD4(+) donor lymphocytes for treatment of relapse after allogeneic bone marrow transplant. Blood. 1998;91(10):3671–80.
Soiffer RJ, et al. Randomized trial of CD8 + T-cell depletion in the prevention of graft-versus-host disease associated with donor lymphocyte infusion. Biol Blood Marrow Transplant. 2002;8(11):625–32.
Anderson BE, et al. Memory CD4 + T cells do not induce graft-versus-host disease. J Clin Invest. 2003;112(1):101–8.
Chen BJ, et al. Transfer of allogeneic CD62L—memory T cells without graft-versus-host disease. Blood. 2004;103(4):1534–41.
Li JM, et al. Separating graft-versus-leukemia from graft-versus-host disease in allogeneic hematopoietic stem cell transplantation. Immunotherapy. 2009;1(4):599–621.
Chakraverty R, et al. An inflammatory checkpoint regulates recruitment of graft-versus-host reactive T cells to peripheral tissues. J Exp Med. 2006;203(8):2021–31.
Klingebiel T, Bader P. Delayed lymphocyte infusion in children given SCT. Bone Marrow Transplant. 2008;41(Suppl 2):S23–6.
Chakraverty R, et al. Host MHC class II + antigen-presenting cells and CD4 cells are required for CD8-mediated graft-versus-leukemia responses following delayed donor leukocyte infusions. Blood. 2006;108(6):2106–13.
Billiau AD, et al. Crucial role of timing of donor lymphocyte infusion in generating dissociated graft-versus-host and graft-versus-leukemia responses in mice receiving allogeneic bone marrow transplants. Blood. 2002;100(5):1894–902.
Kernan NA, et al. Clonable T lymphocytes in T cell-depleted bone marrow transplants correlate with development of graft-v-host disease. Blood. 1986;68(3):770–3.
Mackinnon S, et al. Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease. Blood. 1995;86(4):1261–8.
Sad S, Mosmann TR. Single IL-2-secreting precursor CD4 T cell can develop into either Th1 or Th2 cytokine secretion phenotype. J Immunol. 1994;153(8):3514–22.
Sad S, Marcotte R, Mosmann TR. Cytokine-induced differentiation of precursor mouse CD8 + T cells into cytotoxic CD8 + T cells secreting Th1 or Th2 cytokines. Immunity. 1995;2(3):271–9.
Fowler DH, et al. Allospecific CD4 + , Th1/Th2 and CD8 + , Tc1/Tc2 populations in murine GVL: type I cells generate GVL and type II cells abrogate GVL. Biol Blood Marrow Transplant. 1996;2(3):118–25.
Yonemura Y, et al. Effects of interleukin-11 on carboplatin-induced thrombocytopenia in rats and in combination with stem cell factor. Int J Hematol. 1997;65(4):397–404.
Krijanovski OI, et al. Keratinocyte growth factor separates graft-versus-leukemia effects from graft-versus-host disease. Blood. 1999;94(2):825–31.
Antin JH, et al. A phase I/II double-blind, placebo-controlled study of recombinant human interleukin-11 for mucositis and acute GVHD prevention in allogeneic stem cell transplantation. Bone Marrow Transplant. 2002;29(5):373–7.
Couriel D, et al. Tumor necrosis factor-alpha blockade for the treatment of acute GVHD. Blood. 2004;104(3):649–54.
Fowler DH, et al. Clinical “cytokine storm” as revealed by monocyte intracellular flow cytometry: correlation of tumor necrosis factor alpha with severe gut graft-versus-host disease. Clin Gastroenterol Hepatol. 2004;2(3):237–45.
Ferrara JL, Abhyankar S, Gilliland DG. Cytokine storm of graft-versus-host disease: a critical effector role for interleukin-1. Transplant Proc. 1993;25(1 Pt 2):1216–7.
Hill GR, et al. Differential roles of IL-1 and TNF-alpha on graft-versus-host disease and graft versus leukemia. J Clin Invest. 1999;104(4):459–67.
Korngold R, et al. Role of tumor necrosis factor-alpha in graft-versus-host disease and graft-versus-leukemia responses. Biol Blood Marrow Transplant. 2003;9(5):292–303.
Taylor PA, et al. Targeting of inducible costimulator (ICOS) expressed on alloreactive T cells down-regulates graft-versus-host disease (GVHD) and facilitates engraftment of allogeneic bone marrow (BM). Blood. 2005;105(8):3372–80.
Merad M, et al. Depletion of host Langerhans cells before transplantation of donor alloreactive T cells prevents skin graft-versus-host disease. Nat Med. 2004;10(5):510–7.
Chen W, et al. Cross-priming of CD8 + T cells by viral and tumor antigens is a robust phenomenon. Eur J Immunol. 2004;34(1):194–9.
Anderson BE, et al. Distinct roles for donor- and host-derived antigen-presenting cells and costimulatory molecules in murine chronic graft-versus-host disease: requirements depend on target organ. Blood. 2005;105(5):2227–34.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Zhang, P., Chen, B.J. & Chao, N.J. Prevention of GVHD without losing GVL effect: windows of opportunity. Immunol Res 49, 49–55 (2011). https://doi.org/10.1007/s12026-010-8193-7
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12026-010-8193-7